Please assess the completion status of the following clinical trial:

Trial Title: Dornase Alfa for ARDS in Patients With Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 18 years~* Hospitalized and mechanically ventilated for illness related to SARS-CoV-2~* Confirmed positive SARS-CoV-2 infection by Polymerase chain reaction (PCR)~* individual or surrogate ability to sign informed consent~* negative, urine-based pregnancy test in females~Exclusion Criteria:~* contraindication or intolerance to dornase alfa~* mechanical ventilation expected to be less than 48 hours~* life expectancy less than 24 hours based upon judgement of treating physician~* pregnant~* inability to obtain informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Inhaled/nebulized dornase alfa (Type: EXPERIMENTAL): Patient to receive inhaled/nebulized dornase alfa (Pulmozyme) 2.5 mg twice daily in the ventilator circuit for 3 days, along with standard of care for ARDS.
- Standard of care (Type: NO_INTERVENTION): Standard of care provided for ARDS.

Based on this trial design, predict the completion outcome and termination type (if applicable).